SG11202009933WA - Bcl-2 INHIBITORS - Google Patents
Bcl-2 INHIBITORSInfo
- Publication number
- SG11202009933WA SG11202009933WA SG11202009933WA SG11202009933WA SG11202009933WA SG 11202009933W A SG11202009933W A SG 11202009933WA SG 11202009933W A SG11202009933W A SG 11202009933WA SG 11202009933W A SG11202009933W A SG 11202009933WA SG 11202009933W A SG11202009933W A SG 11202009933WA
- Authority
- SG
- Singapore
- Prior art keywords
- bcl
- inhibitors
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018085217 | 2018-04-29 | ||
| CN2018107134 | 2018-09-21 | ||
| PCT/CN2019/085001 WO2019210828A1 (en) | 2018-04-29 | 2019-04-29 | Bcl-2 INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202009933WA true SG11202009933WA (en) | 2020-11-27 |
Family
ID=68386968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202009933WA SG11202009933WA (en) | 2018-04-29 | 2019-04-29 | Bcl-2 INHIBITORS |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11420968B2 (en) |
| EP (1) | EP3788042A4 (en) |
| JP (1) | JP2021521138A (en) |
| KR (1) | KR20210005677A (en) |
| CN (3) | CN112437772B (en) |
| AU (1) | AU2019264475A1 (en) |
| BR (1) | BR112020022092A2 (en) |
| CA (1) | CA3098348A1 (en) |
| MX (2) | MX2020011495A (en) |
| SG (1) | SG11202009933WA (en) |
| TW (1) | TW202043217A (en) |
| WO (1) | WO2019210828A1 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110177788B (en) | 2017-01-07 | 2023-03-24 | 重庆复创医药研究有限公司 | Compounds as BCL-2 selective apoptosis inducers |
| SI3612531T1 (en) | 2017-04-18 | 2022-11-30 | Shanghai Fochon Pharmaceutical Co., Ltd. | Apoptosis-inducing agents |
| WO2019139902A1 (en) | 2018-01-10 | 2019-07-18 | Zeno Royalties & Milestones, LLC | Benzamide compounds |
| US11420968B2 (en) * | 2018-04-29 | 2022-08-23 | Beigene, Ltd. | Bcl-2 inhibitors |
| US20220073513A1 (en) | 2018-12-29 | 2022-03-10 | Newave Pharmaceutical Inc. | 1h-pyrrolo[2,3-b]pyridine derivatives and related compounds as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| CN114929689A (en) * | 2019-10-28 | 2022-08-19 | 百济神州有限公司 | Bcl-2 inhibitors |
| WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
| CA3160417A1 (en) | 2019-12-06 | 2021-06-10 | Loxo Oncology, Inc. | Dosing of a bruton's tyrosine kinase inhibitor |
| WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| AU2021256580A1 (en) * | 2020-04-15 | 2022-09-29 | Beigene, Ltd. | Bcl-2 inhibitor |
| WO2021223736A1 (en) * | 2020-05-08 | 2021-11-11 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2 inhibitors |
| WO2022089463A1 (en) * | 2020-10-28 | 2022-05-05 | 杭州和正医药有限公司 | Bcl-2 protein apoptosis-inducing agent and application thereof |
| CN117642157A (en) * | 2021-03-19 | 2024-03-01 | 伊尔治疗学股份有限公司 | Compounds having ((3-nitrophenyl) sulfonyl) acetamide as BCL-2 inhibitors |
| CN117616023A (en) * | 2021-04-13 | 2024-02-27 | 爱新医药科技(香港)有限公司 | BCL-2 or BCL-2/BCL-XL modulators and uses thereof |
| AU2022286958A1 (en) * | 2021-06-02 | 2023-12-21 | Beigene Switzerland Gmbh | Methods of treating b-cell malignancy using bcl-2 inhibitor |
| CN115490708A (en) * | 2021-06-18 | 2022-12-20 | 苏州亚盛药业有限公司 | Sulfonamide macrocyclic derivatives, and preparation method and application thereof |
| TW202328125A (en) * | 2021-08-31 | 2023-07-16 | 英屬開曼群島商百濟神州有限公司 | Solid forms of bcl-2 inhibitors, method of preparation, and use thereof |
| WO2023078398A1 (en) * | 2021-11-05 | 2023-05-11 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2 inhibitors |
| WO2023088167A1 (en) * | 2021-11-20 | 2023-05-25 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2 inhibitors |
| CN116217566A (en) * | 2021-12-06 | 2023-06-06 | 杭州和正医药有限公司 | Anti-apoptosis protein BCL-2 inhibitor, pharmaceutical composition and application thereof |
| TW202400163A (en) | 2022-05-12 | 2024-01-01 | 英屬開曼群島商百濟神州有限公司 | Methods of treating myeloid malignancies using bcl-2 inhibitor |
| WO2023231777A1 (en) * | 2022-06-01 | 2023-12-07 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2 inhibitors |
| WO2024017354A1 (en) * | 2022-07-21 | 2024-01-25 | Beigene, Ltd. | Methods of treating multiple myeloma using bcl-2 inhibitor |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY26942A1 (en) | 2000-09-20 | 2002-04-26 | Abbott Lab | PROMOTING N-ACILSULFONAMIDS OF APOPTOSIS |
| US20020055631A1 (en) * | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| KR20070046180A (en) | 2004-08-20 | 2007-05-02 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
| ES2493466T3 (en) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Apoptosis promoters |
| WO2006127364A1 (en) | 2005-05-24 | 2006-11-30 | Abbott Laboratories | Apoptosis promoters |
| CA2662320C (en) | 2006-09-05 | 2014-07-22 | Abbott Laboratories | Bcl inhibitors treating platelet excess |
| WO2009036051A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors containing a zinc binding moiety |
| CN102112445B (en) | 2008-06-09 | 2014-06-18 | 百时美施贵宝公司 | Hydroxyphenylsulfonamides as antiapoptotic Bcl inhibitors |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| UA108193C2 (en) | 2008-12-04 | 2015-04-10 | APOPTOZINDUCE FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTO-IMMUNE DISEASES | |
| HUE029289T2 (en) | 2008-12-05 | 2017-02-28 | Abbvie Inc | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| EP2373629B1 (en) | 2008-12-08 | 2013-04-10 | Boehringer Ingelheim International Gmbh | Compounds for treating cancer |
| DK2511264T3 (en) | 2009-01-19 | 2015-06-22 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| SG172393A1 (en) | 2009-01-19 | 2011-07-28 | Abbott Lab | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| PE20120345A1 (en) * | 2009-05-26 | 2012-05-17 | Abbvie Bahamas Ltd | DERIVATIVES OF 2- (1H-PIRROLO [2,3-B] PYRIDIN-5-ILOXI) -N-FENYLSULFONYLBENZAMIDE AS INHIBITORS OF ANTI-APOPTOTIC PROTEINS |
| KR20120078715A (en) | 2009-09-10 | 2012-07-10 | 노파르티스 아게 | Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer |
| JP5959501B2 (en) | 2010-03-25 | 2016-08-02 | アッヴィ・インコーポレイテッド | Apoptosis inducers for the treatment of cancer and immune and autoimmune diseases |
| TWI520960B (en) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI535712B (en) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | Chemical compounds |
| KR20180059560A (en) | 2010-10-29 | 2018-06-04 | 애브비 인코포레이티드 | Solid dispersions containing an apoptosis-inducing agent |
| IT1403156B1 (en) | 2010-12-01 | 2013-10-04 | Università Degli Studi Di Torino | PHOSPHATIDYLINOSITOL 3-CHINASE INHIBITORS, RELATED COMPOSITIONS AND USES. |
| US8691184B2 (en) * | 2011-01-25 | 2014-04-08 | The Regents Of The University Of Michigan | Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same |
| WO2012162365A1 (en) | 2011-05-25 | 2012-11-29 | Bristol-Myers Squibb Company | Substituted sulfonamides useful as antiapoptotic bcl inhibitors |
| CN104039797B (en) | 2011-10-12 | 2016-06-01 | 南京奥昭生物科技有限公司 | As the heterocyclic molecular of cell death inducer |
| CA2859876A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
| CA2859869A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
| BR112014015308A2 (en) | 2011-12-23 | 2017-06-13 | Novartis Ag | compounds for inhibiting bcl2 interaction with binding counterparts |
| CA2859873A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
| US9126980B2 (en) | 2011-12-23 | 2015-09-08 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| WO2013185202A1 (en) | 2012-06-14 | 2013-12-19 | Beta Pharma Canada Inc | Apoptosis inducers |
| US9096625B2 (en) | 2013-01-16 | 2015-08-04 | The Regents Of The University Of Michigan | BCL-2/BCL-XL inhibitors and therapeutic methods using the same |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EP3481397A1 (en) | 2016-07-06 | 2019-05-15 | Concert Pharmaceuticals Inc. | Deuterated venetoclax |
| RU2722560C1 (en) | 2016-08-05 | 2020-06-01 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
| WO2018041248A1 (en) | 2016-09-01 | 2018-03-08 | 北京赛林泰医药技术有限公司 | Bcl-2 selective inhibitor and preparation and use thereof |
| CN106565706B (en) | 2016-10-27 | 2018-05-01 | 广东东阳光药业有限公司 | A kind of sulfamide derivative and its application in pharmacy |
| CN106749233B (en) * | 2016-11-24 | 2020-04-21 | 中山大学 | Sulfonamide derivatives and application thereof |
| US11420968B2 (en) | 2018-04-29 | 2022-08-23 | Beigene, Ltd. | Bcl-2 inhibitors |
| US20220073513A1 (en) | 2018-12-29 | 2022-03-10 | Newave Pharmaceutical Inc. | 1h-pyrrolo[2,3-b]pyridine derivatives and related compounds as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
-
2019
- 2019-04-29 US US17/050,581 patent/US11420968B2/en active Active
- 2019-04-29 KR KR1020207033817A patent/KR20210005677A/en not_active Application Discontinuation
- 2019-04-29 CN CN201980029015.1A patent/CN112437772B/en active Active
- 2019-04-29 BR BR112020022092-2A patent/BR112020022092A2/en unknown
- 2019-04-29 CA CA3098348A patent/CA3098348A1/en active Pending
- 2019-04-29 WO PCT/CN2019/085001 patent/WO2019210828A1/en unknown
- 2019-04-29 SG SG11202009933WA patent/SG11202009933WA/en unknown
- 2019-04-29 EP EP19797052.8A patent/EP3788042A4/en active Pending
- 2019-04-29 CN CN202311486964.7A patent/CN117683029A/en active Pending
- 2019-04-29 MX MX2020011495A patent/MX2020011495A/en unknown
- 2019-04-29 JP JP2020555218A patent/JP2021521138A/en active Pending
- 2019-04-29 CN CN202311185016.XA patent/CN117430601A/en active Pending
- 2019-04-29 AU AU2019264475A patent/AU2019264475A1/en active Pending
-
2020
- 2020-04-28 TW TW109114185A patent/TW202043217A/en unknown
- 2020-10-29 MX MX2023001689A patent/MX2023001689A/en unknown
-
2022
- 2022-05-23 US US17/750,821 patent/US20220402915A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3788042A1 (en) | 2021-03-10 |
| US20220402915A1 (en) | 2022-12-22 |
| CN112437772A (en) | 2021-03-02 |
| US20210269433A1 (en) | 2021-09-02 |
| CA3098348A1 (en) | 2019-11-07 |
| TW202043217A (en) | 2020-12-01 |
| JP2021521138A (en) | 2021-08-26 |
| CN112437772B (en) | 2023-11-21 |
| AU2019264475A1 (en) | 2020-11-12 |
| BR112020022092A2 (en) | 2021-02-02 |
| KR20210005677A (en) | 2021-01-14 |
| CN117430601A (en) | 2024-01-23 |
| MX2020011495A (en) | 2021-01-15 |
| MX2023001689A (en) | 2023-02-22 |
| EP3788042A4 (en) | 2022-01-26 |
| CN117683029A (en) | 2024-03-12 |
| US11420968B2 (en) | 2022-08-23 |
| WO2019210828A1 (en) | 2019-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202009933WA (en) | Bcl-2 INHIBITORS | |
| IL283639A (en) | Kif18a inhibitors | |
| IL291430A (en) | Mcl-1 inhibitors | |
| FI3672976T3 (en) | Bcl-2 inhibitors | |
| IL269196A (en) | Novel inhibitors | |
| ZA202006327B (en) | Magl inhibitors | |
| IL276813A (en) | Arginase inhibitors | |
| IL277778B (en) | Bcl6 inhibitors | |
| GB201807014D0 (en) | Factor xlla inhibitors | |
| SG11202010914YA (en) | Furin inhibitors | |
| ZA201907136B (en) | Ip6k inhibitors | |
| IL289622A (en) | Bcl-2 protein inhibitors | |
| IL276013A (en) | Pi4kiiibeta inhibitors | |
| EP3600301A4 (en) | Kdm4 inhibitors | |
| IL283309A (en) | Rip1 inhibitors | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| IL274550A (en) | Dopamine-b-hydroxylase inhibitors | |
| GB202014309D0 (en) | Refrigerating apparatus | |
| IL279419A (en) | Ccl5 inhibitors | |
| GB201812462D0 (en) | Inhibitors | |
| GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| GB201809939D0 (en) | Eastase inhibitor | |
| GB201721465D0 (en) | Inhibitors |